By Robb M. Stewart
Seelos Therapeutics’ board has given the green light to a 1-for-30 reverse stock split in an effort to regain compliance with Nasdaq’s minimum bid price requirement of $1 a share.
The clinical-stage biopharmaceutical company, which last month hired Canaccord Genuity to help with a review of potential partnerships, collaborations…
Master your money.
Subscribe to MarketWatch.
Get this article and all of MarketWatch.
Access from any device. Anywhere. Anytime.
Subscribe Now
Already a subscriber?
Log In
Read the full article here